Coronavirus SARS-CoV-2 has turned the whole world upside down. After weeks of curfew to relieve the national health care systems, the economic impact becomes more and more perceptible: We are facing a substantial crisis. The only way out of this misery is finding a) an effective drug for the treatment of COVID-19 or b) a safe vaccine, which prevents us from a Coronavirus infection.
It is still winter outside, and some may wish warmer temperatures to come soon. While humans sometimes need warmth to get going, cold-inducible promoters from Chinese Hamster Ovary (CHO) cells turned out to be interesting tools for the production of biopharmaceuticals at low temperatures.
Automation is the future of numerous processes – not only in our everyday life but also in more specialized areas such as bioprocessing. Researchers are eager to find solutions in order to replace routine steps by automated process sections. This gives them the opportunity to spend the gained time on more meaningful things: thinking about new innovations!
While currently most production processes for biopharmaceuticals are assessed by laboriuos and time-consuming off-line analytics, a new process enables the monitoring of such processes in real-time. Sensors combined with mathematical models deliver information on the quality and quantity of the product, as well as on content and profile impurities. This allows an instant monitoring of processes, making processes safer, faster, cheaper and more efficient.
Scientists from the Department of Biotechnology at the University of Natural Resources and Life Sciences (BOKU) Vienna and the Austrian Centre of Industrial Biotechnology (acib) discovered a gene switch in yeast, that was able to change twelve genes – and thereby the metabolic process of yeast as a whole. This work explains evolutionary events that happened more than 120 million years ago. The results have recently been published in the scientific journal Nature Communications and have the potential to be used in the food and feed industry and for the production of bio fuels and new building blocks for bioplastics.
An interdisciplinary team of scientists is pioneering the development of synthetic glycobiology and trains 15 young researchers in the enabling technologies that underpin the development and exploitation of glycoscience: An exciting topic that promises to bring innovative solutions for the future!
The responsible transport gene that allows the production of lemon acid in large quantities was recently discovered. A breakthrough!
What lies behind the data shown on a LCD screen? What do the numbers express and moreover, can we trust them? Is the value displayed correct and can we deduct the right conclusion to set a responsive course of action?
Did you know that nowadays bacteria and mammalian cells, especially hamster cells, produce a wide range of drugs? And who tells them to do so? The answer is the four-letter code of DNA. Biotechnologists spend a lot of time to explore natural DNA sequences of different organisms for production. The Chinese Hamster is a mammalian system and suits well for cell factories because of its similarity to human cells. However, for a long time the knowledge about the hamster DNA sequence had many gaps that needed to be investigated.
Co-author: Martin Walpot
In the development of drugs and pharmaceutical compounds, expensive tests are necessary, to know, which metabolic by-products and side-effects could emerge and to ensure that drugs are working effectively and in a safe manner. Human-like CYP450 enzymes, which mimic the same activities happening in the human body, are new, excellent biocatalytic tools to screen side effects outside the human body. They also enable the timely production of reasonable amounts of active pharmaceutical ingredients. Used as biocatalysts in industrial applications, new CYP450 enzymes, developed in the EU-project ROBOX, have the potential to speed up drug development, enhance pharmaceutical safety and to innovate chemical markets such as flavour-, fragrance or food industries.